A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can vary from causing mild, cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by stimulating the mother’s body’s defences to generate defence proteins, which are then passed to the foetus through the placenta. This mother-derived protection offers newborns with instant defence from the point of delivery, exactly when they are highly susceptible to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence suggesting that a two-week gap is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to have the vaccine on schedule, whilst noting that protection can still occur even if administered later in the third trimester.
- Nearly 85 per cent coverage when immunised four weeks before birth
- Maternal antibodies transferred through placenta safeguard newborns from birth
- Coverage possible with 2-week gap before early delivery
- Vaccination during the third trimester still offers significant infant protection
Compelling evidence from the latest research
The efficacy of the RSV vaccine administered during pregnancy has been established through a extensive research programme undertaken in England, reviewing data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately 90% of all births during that six-month period, providing strong and reliable evidence of the vaccine’s actual performance. The study’s results have been validated by the UK Health Security Agency as showing strong protection for newborns during their most critical early weeks. The scale of this research provides healthcare professionals and parents-to-be with assurance in the vaccine’s demonstrated effectiveness across different groups and contexts.
The results paint a compelling picture of the vaccine’s protective effectiveness. More than 4,500 babies were treated in hospital with RSV during the study period, with the great majority being infants whose mothers had not been given the vaccination. This stark contrast emphasises the vaccine’s critical role in preventing serious illness in newborns. The decrease in hospital admissions surpassing 80 per cent represents a significant public health achievement, possibly preventing thousands of infants from experiencing the distressing and potentially serious symptoms associated with severe RSV infection. These findings support the importance of the vaccination programme introduced in the UK in 2024.
Study methodology and scope
The research examined birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine clear comparisons of RSV infection levels and hospital admissions. The large sample size and comprehensive nature of the data collection ensured that findings were statistically significant and representative of the broader population, rather than individual cases or small subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to determine the least amount of time between vaccination and birth for optimal protection, as well as to determine whether protection remained meaningful with briefer timeframes. The methodology assessed real-world outcomes rather than controlled laboratory conditions, providing tangible evidence of how the vaccine performs when administered across diverse clinical settings and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and its threats
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from minor cold-type symptoms to severe, life-threatening chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during busier periods.
The infection triggers inflammation deep within the lungs and airways, making it dangerously difficult for affected infants to feed and breathe adequately. Parents often witness their babies struggling visibly, their chests heaving as they attempt to draw enough air into their compromised lungs. Whilst most infants recover with clinical support, a limited though important group succumb from RSV complications each year, making immunisation programmes a vital health service imperative for defending the youngest and most at-risk people in our communities.
- RSV produces inflammation in lungs, causing severe breathing difficulties in babies
- Half of all newborns catch the virus during their first few months alive
- Symptoms span from mild colds to serious chest infections that threaten life requiring hospitalisation
- Over 20,000 UK infants require serious hospital care for RSV each year
- Small numbers of infants die from RSV complications each year in the UK
Adoption rates and specialist advice
Since the RSV vaccine programme began in 2024, health officials have emphasised the importance of pregnant women receiving their jab at the ideal time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing is crucial for guaranteeing newborns benefit from the most robust immunity from birth. Whilst the research shows that vaccination performed at least four weeks prior to delivery delivers nearly 85% protection, experts advise women to get their vaccine as early as possible from 28 weeks of pregnancy forward to increase the antibodies transferred to their babies through the placenta.
The communication from health authorities stays clear: pregnant women ought to prioritise vaccination during their final three months, even if circumstances mean they cannot get vaccinated at the ideal window. Dr Watson has reassured pregnant women that protection is still achievable with shorter intervals between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This flexible approach acknowledges the practical demands of pregnancy whilst ensuring strong safeguarding for at-risk infants during their most critical early months when RSV poses the greatest risk of severe infection.
Regional differences in vaccination
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have differed across various areas and NHS trusts. Certain regions have achieved higher vaccination coverage among eligible pregnant women, whilst others remain focused to boost understanding and access to the jab. These regional differences reflect differences across healthcare infrastructure, communication strategies, and community involvement initiatives, though the overall statistics demonstrates robust and reliable protection irrespective of geographical location.
- NHS trusts rolling out varied communication campaigns to connect with women during pregnancy
- Regional disparities in immunisation take-up in different parts of England require targeted improvement
- Regional health providers tailoring initiatives to align with community needs and circumstances
Real-world impact and parental perspectives
The vaccine’s remarkable effectiveness translates into real advantages for families across the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the rollout of this safeguarding intervention, the 80% decrease in admissions represents thousands of infants spared from severe infection. Parents no longer face the troubling prospect of seeing their babies struggle for breath or struggle to eat, symptoms that define serious RSV disease. The vaccine has markedly changed the terrain of neonatal respiratory health, offering expectant mothers a active means to shield their youngest infants during those crucial first weeks.
For families like that of Malachi, whose severe RSV infection led to devastating brain damage, the vaccine’s introduction carries deep personal significance. His mother’s support of the jab underscores the profound consequences that vaccine-preventable disease can inflict on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story strikes a chord with parents now provided with protection. The knowledge that such serious complications—hospital stay, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to expectant mothers navigating their late pregnancy, changing what was once an unavoidable seasonal threat into a manageable risk.